SecBot SecBot
8-K ·Filed Jul 13, 2026

QTTB

Q32 Bio Inc.
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001193125-26-301520
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The robust efficacy and clean safety profile de-risk bempikibart's path to registration in alopecia areata. Monitor for FDA feedback and initiation of Phase 3 trial in 1H27, which could drive significant upside for this $190M market cap biotech. The data also supports expansion into other I&I indications.

DirectionBullish
Confidencehigh
Horizonmonths

bempikibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
Next catalyst
None dated

What to watchThe July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$21.38
T+0 close · Jul 13, 2026 · via day close
Latest settled
−62.07%
T+60 · $8.11
Vs SPY
−66.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $21.38entry
  2. T+1 · 4mo ago −13.66%α −14.01% · $18.46
  3. T+5 · 4mo ago −29.61%α −28.82% · $15.05
  4. T+20 · 3mo ago −26.71%α −29.89% · $15.67
  5. T+60 · 6w ago −62.07%α −66.06% · $8.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata. The mITT population (n=25) showed a 35.3% mean SALT reduction and 40.0% SALT-20 response, with no Grade 3 or higher adverse events and negligible anti-drug antibodies. The company plans to advance to a registration-directed program and engage the FDA in 1H27, supporting a differentiated biologic profile in a >$5B US market opportunity.

Key Facts

  • Part B mITT (n=25): 35.3% mean SALT reduction at Week 36; SALT-20 response 40.0% (10/25)
  • ITT (n=33): SALT-20 response 30.3% (10/33)
  • No Grade 3 or higher AEs; injection site reactions in 4% of administrations, all mild
  • Negligible anti-drug antibodies with no impact on pharmacokinetics
  • Plans to initiate registration-directed program in 1H27 after FDA engagement
  • US alopecia areata market estimated >$5B by 2037

Financial Impact

No financial data in filing; positive clinical data supports potential for partnership or funding for registrational trials

Risk Factors

  • Small sample size (n=25 mITT) limits statistical power; results may not replicate in larger trials
  • Company will need additional capital to fund registrational trials; dilution risk
  • Competition from JAK inhibitors with established market presence and black box warnings may limit uptake

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-301520
Document: d143274d8k.htm0001193125-26-301520
Document: 0001193125-26-301520-index-headers.html0001193125-26-301520
Document: 0001193125-26-301520-index.html0001193125-26-301520
Document: 0001193125-26-301520.txt0001193125-26-301520

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026